Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16077-e16077
Author(s):  
Ugo De Giorgi ◽  
Giuseppe Procopio ◽  
Roberto Sabbatini ◽  
Claudia Caserta ◽  
Manfred Mitterer ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Renal Cell ◽  
Performance Status ◽  
Univariate Analysis ◽  
Cell Cancer ◽  
Cell Aging ◽  
Lymphocyte Ratio ◽  
Risk Of Death ◽  
High Bmi

e16077 Background: Body mass index (BMI) and inflammation indexes are easily evaluated, predict survival in many tumors, and are potentially modifiable. The "obesity paradox" of longer survival in cancer patients with high BMI has been explained by altered fatty acid pathways, which could have an impact in immune-inflammatory function, and leptin-driven increase in T cell aging resulting in higher PD-1 expression and dysfunction, which leaves tumors notably more sensitive to checkpoint blockade. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of metastatic renal cell carcinoma (mRCC) undergoing immune checkpoint inhibitor therapy. Methods: A prospective cohort of patients with mRCC treated with nivolumab enrolled in the Italian Expanded Access Program (EAP) from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil to lymphocyte ratio (NLR) < /≥3, systemic immune-inflammation index (SII) < /≥3 and platelet to lymphocyte ratio (PLR) < /≥232. Patients were classified as high BMI (≥25 kg/m2) versus normal BMI ( < 25 kg/m2). Results: Among 313 evaluable patients, 289 (75.1%) were male, median age was 65 years (range, 40 to 84), with 105 (24.9%) ≥70 years. In univariate analysis, age ≥70 years, performance status, BMI, SII, NLR and PLR were able to predict outcome. In multivariate analyses, SII ≥1375, BMI < 25 and age ≥70 years independently predicted OS (HR, 2.96; 95% CI, 2.05-4.27; HR, 1.59; 95% CI, 1.10-2.30 and HR, 1.65; 95% CI, 1.07-2.55, respectively). Under the model of independent effects, a patient with both SII ≥1375 and BMI < 25 was estimated to have much worse OS (HR, 3.37; 95% CI, 2.29-4.95, p < 0.0001) than a patient with neither or only one risk factor. SII changes at 3 months predicted OS (P < 0.0001). Conclusions: BMI combined with inflammation tripled the risk of death, suggesting that these biomarkers are critical prognostic factors for OS in patients with mRCC treated with nivolumab.

Blood-based-inflammation-markers, body mass index, and survival of nonmetastatic esophageal cancer.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 324-324
Author(s):  
Wanning Wang ◽  
Joelle Soriano ◽  
Tyler Soberano ◽  
Katrina Hueniken ◽  
M. Catherine Brown ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Esophageal Cancer ◽  
Body Mass ◽  
Cox Regression ◽  
Locally Advanced ◽  
Continuous Variables ◽  
Inflammation Markers ◽  
Lymphocyte Ratio ◽  
Risk Of Death ◽  
High Bmi

324 Background: Blood-based-inflammation-markers (BBIM) and Body Mass Index (BMI) have been associated with overall survival (OS) in a number of cancers. Inflammation and obesity have biological interactions. We evaluated the role of Neutrophil-to-Lymphocyte-Ratio (NLR), Platelet-to-Lymphocyte-Ratio (PLR) and Systemic-Inflammation-Index (SII) in conjunction with BMI as predictors of OS in localized/locally-advanced-esophageal cancer (LEC/LAEC). Methods: LEC/LAEC patients treated from 2006-2014 had the following variables analyzed both as continuous and categorical: BMI (low <25 kg/m2, high ≥25 kg/m2), NLR (low <4, high ≥4), PLR (low <232, high ≥232), and SII (low <1375, high ≥1375), with OS. Univariate (UVA) and Multivariate analysis (MVA) were analyzed using Cox regression (adjusted hazard ratios, aHR; 95% Confidence Intervals, CI). MVA models of OS were built, assessing different categorical combinations of BBIM factors with and without BMI. Results: Of 411 pts, 79% were males, median age was 63.5 years, 67% were adenocarcinomas; Stage I/II/III: 14%, 28%, 59%; Median BMI was 26.5kg/m2 and BMI distribution was: 3% underweight, 40% normal weight, 37% overweight and 20% obese. After a median follow-up of 87 months, 204 pts recurred, and 257 died. In MVA, BMI alone had no impact on OS (aHR 0.89, CI 0.7-1.1, p=0.15); individually as continuous variables, higher SII (p=0.03) and higher NLR (p=0.006) were inversely associated with OS whereas higher PLR was not (p=0.10). In an MVA of categorical combinations of BMI and BBIM on OS, patients in the high-BMI/low-PLR group were at lower risk of death when compared to all other groups (aHR=0.65, 95%CI:0.5-0.8, p=0.007). Similar non-statistically significant trends were shown when SII and NLR were individually combined with BMI (aHR=0.77, 95%CI:0.6-1.0, p=0.09; aHR=0.74, 95%CI:0.5-1.0, p=0.05, respectively). Conclusions: Our results suggest that in LEC/LAEC pts, high BMI and low PLR together are associated with improved OS when compared to pts with low BMI and/or high PLR. NLR and SII alone were associated with OS. Further studies evaluating the underlying mechanisms of BBMI, in particular PLR and inflammation/obesity are warranted.

Prognostic significance of body mass index in breast cancer patients with hormone receptor-positive tumours after curative surgery

2013 ◽  
Vol 36 (6) ◽  
pp. 297 ◽  
Author(s):  
Peng Xing ◽  
Ji-Guang Li ◽  
Feng Jin ◽  
Ting-Ting Zhao ◽  
Qun Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Hormone Receptor ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Axillary Lymph ◽  
Nodal Stage ◽  
Hormone Receptor Positive ◽  
High Bmi

Purpose: Obesity has been recognized as a significant risk factor for postmenopausal breast cancer. The aim of this study is to investigate the prognostic significance of body mass index (BMI) in hormone receptor-positive, operable breast cancer. Methods: In this retrospective cohort study, 1,192 consecutive patients with curative resection of primary breast cancer were enrolled. Patients were assigned to two groups according to BMI: normal or underweight (BMI < 23.0 kg/m2) and overweight or obese (BMI ≥23.0 kg/m2). Associations among BMI and clinicopathological characteristics and prognosis of patients were assessed. Results: A high BMI was significantly (P < 0.01) correlated with age, nodal stage, ALNR, ER positivity, PR positivity and menopausal status at diagnosis. Univariate analysis revealed that BMI, pathologic T stage, nodal stage, axillary lymph node ratio (ALNR) and adjuvant radiotherapy history were significantly (P < 0.05) associated with disease-free survival and overall survival, irrespective of tumour hormone receptor status. Multivariate analysis revealed BMI as an independent prognostic factor in all cases and in hormone receptor-positive cases. Conclusion: A high BMI (≥23.0 kg/m^2) is independently associated with poor prognosis in hormone receptor-positive breast cancer.

Systemic immune inflammation index and treatment response in patients with metastatic renal cell cancer.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 591-591 ◽  
Author(s):  
Kadriye Bir Yücel ◽  
Arzu Yasar ◽  
Gokhan Ucar ◽  
Gungor Utkan ◽  
Nuriye Yildirim ◽  
...  
Keyword(s):  
Overall Survival ◽  
Multivariate Analysis ◽  
Treatment Response ◽  
Renal Cell ◽  
Prognostic Value ◽  
Cox Regression ◽  
Performance Status ◽  
Univariate Analysis ◽  
Cell Cancer ◽  
Immune Inflammation

591 Background: To investigate the prognostic value of the pretreatment inflammatory characteristics on treatment response and survival. Methods: We included 151 patients with metastatic renal cell carcinoma (mRCC) Patients’ charts were retrospectively analyzed for their clinical, pathological and demographic features. Systemic immune inflammation index (SII) cut off is estimated with median value. Overall survival (OS) was estimated by Kaplan-Meier method for univariate analysis and Cox-regression for multivariate analysis. Results: In high SII group (SII > 844) overall survival is 11 months and in low SII group (SII < 844) overall survival is 22 months (p = 0,008). Median OS is lower in the hypercalcemic group (7 months vs.18 months, P = 0,013). In patients with anemia and thrombocytosis, OS is lower (41 months vs. 13 months p = 0,001 and 6 months vs. 18 months p = 0,01). In multivariate analysis, anemia, SII, and ECOG performance status were able to predict OS (HR = 2,69, HR = 2,04, HR = 2,57) Conclusions: In patients with mRCC, SII may have a prognostic value and higher score may related with decreased overall survival.

scholarly journals Body Mass Index and Renal Cell Cancer

Epidemiology ◽  
2012 ◽  
Vol 23 (6) ◽  
pp. 821-828 ◽  
Author(s):  
Jennifer L. Beebe-Dimmer ◽  
Joanne S. Colt ◽  
Julie J. Ruterbusch ◽  
Gregory R. Keele ◽  
Mark P. Purdue ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer

scholarly journals Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

2019 ◽  
Vol 25 (13) ◽  
pp. 3839-3846 ◽  
Author(s):  
Ugo De Giorgi ◽  
Giuseppe Procopio ◽  
Diana Giannarelli ◽  
Roberto Sabbatini ◽  
Alessandra Bearz ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Systemic Inflammation ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer

Influence of Body Mass Index and Smoking on the Long-Term Survival of Patients With Renal Cell Cancer

2013 ◽  
Vol 11 (4) ◽  
pp. 458-464 ◽  
Author(s):  
Kaisa Leea Sunela ◽  
Matti Jorma Kataja ◽  
Pirkko-Liisa Irmeli Kellokumpu-Lehtinen
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Inverse association between body mass index and all-cause mortality in rural chinese adults: 15-year follow-up of the Anqing cohort study

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e045495
Author(s):  
Jie Yang ◽  
Nannan Cheng ◽  
Yue Zhang ◽  
Lijing Ye ◽  
Jingyi Li ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Cohort Study ◽  
Body Mass ◽  
Rural Population ◽  
Inverse Association ◽  
Risk Of Death ◽  
All Cause Mortality ◽  
Baseline Bmi ◽  
High Bmi

ObjectiveTo investigate the association between body mass index (BMI) and all-cause mortality in a Chinese rural population.DesignProspective cohort study.SettingThis study was conducted from 2003 to 2018 in Anqing, Anhui Province, China.Participants17 851 participants aged 25–64 years (49.4% female) attending physical examinations and questionnaire were included in this study. The inclusion criterion was families having a minimum of three participating siblings. The exclusion criteria included participants without family number and BMI data at baseline.Outcome measuresThe outcome measure was all-cause mortality. Generalized estimating equation (GEE) regression analysis was performed to determine the association between baseline BMI and all-cause mortality.ResultsDuring a mean follow-up period of 14.1 years, 730 deaths (8.0%) occurred among men, and 321 deaths (3.6%) occurred among women. The mean BMI for males was 21.3±2.5 kg/m2, and for female it was 22.1±3.1 kg/m2. Baseline BMI was significantly inversely associated with all-cause mortality risk for per SD increase (OR, 0.79 (95% CI, 0.72 to 0.87) for males; OR, 0.88 (95% CI, 0.76 to 1.01) for females). When BMI was stratified with cut points at 20 and 24 kg/m2, compared with the low BMI group, a significantly lower risk of death was found in the high BMI group (BMI ≥24: OR, 0.57 (95% CI, 0.43 to 0.77) in males; 0.65 (95% CI, 0.46 to 0.93) in females) after adjustment for relevant factors.ConclusionsIn this relatively lean rural Chinese population, the risk of all-cause mortality decreased with increasing BMI. The excess risk of all-cause mortality associated with a high BMI was not seen among this rural population.

Predictors of mortality in metastatic papillary renal cell cancer.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 509-509 ◽  
Author(s):  
Abhinav Sidana ◽  
Amit L Jain ◽  
Meet Kadakia ◽  
Spencer Krane ◽  
Julia C. Friend ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Univariate Analysis ◽  
Cell Cancer ◽  
Elevated Serum ◽  
Cox Proportional Hazards ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Predictors Of Mortality ◽  
Papillary Type

509 Background: While studies have established several prognostic factors determining mortality in metastatic clear cell renal cell cancer patient, similar analysis has been lacking in metastatic papillary renal cell cancer (pRCC) patients. We aim to determine the predictors of mortality in metastatic pRCC patients. Methods: Retrospective evaluation of the medical records of patients with metastatic pRCC seen at National Cancer Institute (2000-2014) was undertaken. Patient demographics, tumor characteristics, and outcomes were studied. Kaplan-Meier Survival analysis was done to estimate overall survival (OS). Cox proportional-hazards regression analysis was done to identify predictors of All cause mortality (ACM) in this population. Results: 106 consecutive patients with metastatic pRCC were identified. The median age and follow up time after the diagnosis of metastases was 50 years (11-80) and 33.8 mon (2.3-246.7) respectively. Twenty one (19.8%) and 42 (39.6%) patients had papillary type 1 and papillary type 2 renal cancers respectively; in 43 (40.5%) patients, tumors were classified as papillary, not otherwise specified. Half (53) of patients had hereditary origin of pRCC. Median estimated OS of entire cohort was 37.5 mon. There was no difference in survival between patients with hereditary or sporadic pRCC (p = 0.80) or among patients with different subtypes of pRCC (p = 0.79). On univariate analysis, elevated serum corrected calcium elevated lactate dehydrogenase, Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio, and presence of malignant ascites significantly affected the patients’ prognosis. Corrected Calcium (p = 0.03) and NLR (p = 0.004) were found to be independent predictors of ACM on multivariate analysis. Conclusions: To our knowledge, this is the largest single center series evaluating survival and predictors of survival in metastatic pRCC. Metastatic pRCC patients with elevated NLR and serum corrected calcium are significantly associated with relatively poor OS when compared to patients without these findings. If validated in larger multi-institutional cohorts, it might be reasonable to incorporate corrected calcium and NLR in nomograms predicting ACM in metastatic pRCC.

Sign in / Sign up

Export Citation Format

Share Document